The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Open accessPublished version of a preprint
Abstract
PURPOSE: The mechanisms by which trastuzumab imparts clinical benefit remain incompletely understood. Antibody-dependent cellular cytotoxicity via interactions with Fcγ receptors (FcγR) on leukocytes may contribute to its antitumor effects. Single-nucleotide polymorphisms (SNP) in FCGR3A and FCGR2A genes lead to amino acid substitutions at positions 158 and 131, respectively, and affect binding of antibodies to FcγR such that 158V/V and 131H/H bind with highest affinity. This study aimed to determine whether high-affinity SNPs are associated with disease-free survival (DFS) among patients with HER2-positive nonmetastatic breast cancer. EXPERIMENTAL DESIGN: Genomic DNA was isolated from 1,286 patients enrolled in a trial of adjuvant trastuzumab-based chemotherapy. Genotyping was conducted using Sanger sequencing and Sequenom mass spectrometry. RESULTS: Patient samples (N = 1,189) were successfully genotyped for FCGR3A and 1,218 for FCGR2A. Compared with the overall results of the BCIRG006 study, in the subset of patients genotyped in this analysis, a less robust improvement in DFS was observed for the trastuzumab arms than control arm (HR, 0.842; P = 0.1925). When stratified for prognostic features, the HR in favor of trastuzumab was consistent with that of the overall study (HR, 0.74; P = 0.036). No correlation between DFS and FCGR3A/2A genotypes was seen for trastuzumab-treated patients (158V/V vs. V/F vs. F/F, P = 0.98; 131H/H vs. H/R vs. R/R, P = 0.76; 158V/V and/or 131H/H vs. others, P = 0.67). CONCLUSION: This analysis evaluating the association between FCGR3A/2A genotypes and trastuzumab efficacy in HER2-positive breast cancer did not show a correlation between FCGR3A-V/F and FCGR2A-H/R SNPs and DFS in patients treated with trastuzumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We should note, however, that a large trial of trastuzumab-based adjuvant chemotherapy in patients with early HER2+ breast cancer did not show an association between FCGR3A and FCGR2A polymorphisms with patient outcome (Hurvitz et al., 2012)”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Hurvitz et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,563
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,438
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D. J., EIERMANN, W., Robert, N. J., Pieńkowski, T., Martín, M., Press, M. F., Mackey, J. R., Glaspy, J. A., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,833
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,640
SNPStats: a web tool for the analysis of association studies
Solé, X., Guinó, E., Valls, J., Iniesta, R., & Moreno, V. R. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl268 · Cited by 2,011
Cartron, G., Dacheux, L., Salles, G. A., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,954
Research works printed but not linked: 1
- Foster, 2002, FCGR3A V/F polymorphism does not predict response to Herceptin (H) monotherapy, 57a
Cited by
Sorted by citations
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 548
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 417
Rugo, H. S., Im, S., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escrivá-de-Romaní, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7932 · Cited by 348
Natural and therapy-induced immunosurveillance in breast cancer
Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015) · Nature Medicine · doi:10.1038/nm.3944 · Cited by 316
The immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 287
Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 244
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Marshall, M. J. E., Stopforth, R. J., & Cragg, M. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01245 · Cited by 190
Luque-Cabal, M., García‐Teijido, P., Fernández-Pérez, Y., Sánchez‐Lorenzo, L., & Vázquez, I. P. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34537 · Cited by 186
Kodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A. M. M. J., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216078109 · Cited by 153
Current approaches and future directions in the treatment of HER2-positive breast cancer
Hurvitz, S. A., Hu, Y., O’Brien, N. A., & Finn, R. S. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.008 · Cited by 151
The Evolving Landscape of HER2 Targeting in Breast Cancer
Moasser, M. M., & Krop, I. E. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2286 · Cited by 135
Role of Fcγ receptors in HER2-targeted breast cancer therapy
Musolino, A., Gradishar, W. J., Rugo, H. S., Nordstrom, J. L., Rock, E. P., Arnaldez, F. I., & Pegram, M. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003171 · Cited by 142
HER2-positive breast cancer: Current and new therapeutic strategies
Escrivá-de-Romaní, S., Arumí, M., Bellet, M., & Saura, C. (2018) · The Breast · doi:10.1016/j.breast.2018.03.006 · Cited by 132
Zahavi, D. J., Aldeghaither, D. S., O’Connell, A., & Weiner, L. M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby002 · Cited by 135
Griguolo, G., Pascual, T., Dieci, M. V., Guarneri, V., & Prat, A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0548-6 · Cited by 119
Tsao, L.-C., Crosby, E. J., Trotter, T. N., Agarwal, P., Hwang, B.-J., Acharya, C. R., Shuptrine, C. W., Wang, T., Wei, J.-P., Yang, X. Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131882 · Cited by 120
Gavin, P. G., Song, N., Kim, S. R., Lipchik, C., Johnson, N. L., Bandos, H., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4884 · Cited by 115
Fcγ receptors: genetic variation, function, and disease
Hargreaves, C. E., Rose-Zerilli, M. J. J., Machado, L. R., Iriyama, C., Hollox, E. J., Cragg, M. S., & Strefford, J. C. (2015) · Immunological Reviews · doi:10.1111/imr.12341 · Cited by 104
Nagelkerke, S. Q., Schmidt, D. E., de Haas, M., & Kuijpers, T. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02237 · Cited by 94
Perspectives of HER2-targeting in gastric and esophageal cancer
Gerson, J. N., Skariah, S., Denlinger, C. S., & Astsaturov, I. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1315406 · Cited by 93
Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study
Zhang, N., Liu, L., Dumitru, C. D., Houston-Cummings, N. R., Cukan, M. C., Jiang, Y., Li, Y., Li, F., Mitchell, T., Mallem, M. R., et al. (2011) · mAbs · doi:10.4161/mabs.3.3.15532 · Cited by 97
Muntasell, A., Cabo, M., Servitja, S., Tusquets, I., Martinez‐García, M., Rovira, A., Rojo, F., Albanell, J., & López‐Botet, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01544 · Cited by 90
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 104
Rugo, H. S., Im, S., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., Pegram, M. D., Bachelot, T., Wright, G. S., Saura, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02937 · Cited by 87
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
den Besten-Bertholee, D., Maring, J. G., & Kuilenburg, A. B. P. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0450-z · Cited by 79
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
Mandó, P., Rivero, S. G., Rizzo, M., Pinkasz, M., & Levy, E. M. (2021) · The Breast · doi:10.1016/j.breast.2021.08.007 · Cited by 80
HER2-positive breast cancer is lost in translation: time for patient-centered research
Gingras, I., Gebhart, G., de Azambuja, E., & Piccart, M. J. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.96 · Cited by 74
Vivekanandhan, S., & Knutson, K. L. (2022) · Cancers · doi:10.3390/cancers14205115 · Cited by 80
Anti-GD2 MABS and Next-Generation mAb-Based Agents for Cancer Therapy
Horta, Z. P., Goldberg, J. L., & Sondel, P. M. (2016) · Immunotherapy · doi:10.2217/imt-2016-0021 · Cited by 74
Liu, S. D., Chalouni, C. M., Young, J. C., Junttila, T. T., Sliwkowski, M. X., & Lowe, J. B. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0125 · Cited by 76
Roca, L., Dieras, V. C., Roche, H. H., Lappartient, E., Kerbrat, P., Cany, L., Chièze, S., Canon, J.-L. R., Spielmann, M., Penault-Llorca, F. M., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2587-x · Cited by 70
Kurozumi, S., Inoue, K., Takei, H., Matsumoto, H., Kurosumi, M., Horiguchi, J., Takeyoshi, I., & Oyama, T. (2015) · BMC Cancer · doi:10.1186/s12885-015-1641-y · Cited by 68
Lesurf, R., Griffith, O. L., Griffith, M., Hundal, J., Trani, L., Watson, M. A., Aft, R., Ellis, M. J., Ota, D., Suman, V. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx048 · Cited by 68
Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
De, P. K. R., Hasmann, M., & Leyland-Jones, B. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.006 · Cited by 66
Nagelkerke, S. Q., Tacke, C. E. A., Breunis, W. B., Tanck, M. W. T., Geissler, J., Png, E., Hoang, L. T., van der Heijden, J., Naim, A. N. M., Yeung, R. S. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00185 · Cited by 64
Fan, X., Brezski, R. J., Fa, M., Deng, H., Greenplate, A. R., Gonzalez, A. O., Dubinsky, W. P., Strohl, W. R., Jordan, R. E., Zhang, N., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3240 · Cited by 63
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
Kurozumi, S., Inoue, K., Matsumoto, H., Fujii, T., Horiguchi, J., Oyama, T., Kurosumi, M., & Shirabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-52944-6 · Cited by 53
Boero, S., Morabito, A., Banelli, B., Cardinali, B., Dozin, B., Lunardi, G., Piccioli, P., Lastraioli, S., Carosio, R., Salvi, S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0680-0 · Cited by 49
Pharmacogenomics of breast cancer therapy: An update
Westbrook, K. E., & Stearns, V. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.001 · Cited by 49
Kurozumi, S., Padilla, M., Kurosumi, M., Matsumoto, H., Inoue, K., Horiguchi, J., Takeyoshi, I., Oyama, T., Ranger‐Moore, J., Allred, D. C., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3856-2 · Cited by 49
Kurozumi, S., Inoue, K., Matsumoto, H., Fujii, T., Horiguchi, J., Oyama, T., Kurosumi, M., & Shirabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-018-38272-1 · Cited by 49
Norton, N., Olson, R. M., Pegram, M. D., Tenner, K., Ballman, K. V., Clynes, R., Knutson, K. L., & Perez, E. A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0059 · Cited by 48
Biological role of NK cells and immunotherapeutic approaches in breast cancer
Roberti, M. P., Mordoh, J., & Levy, E. M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00375 · Cited by 47
The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer
Avtenyuk, N. U., Visser, N., Bremer, E., & Wiersma, V. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217820 · Cited by 48
Treffers, L. W., Zhao, X. W., van der Heijden, J., Nagelkerke, S. Q., van Rees, D. J., Gonzalez, P., Geissler, J., Verkuijlen, P., van Houdt, M., de Boer, M., et al. (2017) · European Journal of Immunology · doi:10.1002/eji.201747215 · Cited by 42
Kurozumi, S., Fujii, T., Matsumoto, H., Inoue, K., Kurosumi, M., Horiguchi, J., & Kuwano, H. (2017) · Medical Molecular Morphology · doi:10.1007/s00795-017-0170-y · Cited by 42
Muntasell, A., Servitja, S., Cabo, M., Bermejo, B., Pérez‐Buira, S., Rojo, F., Costa-García, M., Arpí, O., Moraru, M., Serrano, L., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0896 · Cited by 40
Zhang, B., Shi, J., Shi, X., Xu, X., Gao, L., Liu, M., Liu, M., Gao, M., Jin, S., Zhou, J., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101068 · Cited by 38
Challenges and prospects in HER2-positive breast cancer-targeted therapy
Li, X., Zhang, X., Yin, S., & Nie, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104624 · Cited by 39
Batalha, S., Cristóvão‐Ferreira, S., & Brito, C. (2021) · Cancers · doi:10.3390/cancers13061305 · Cited by 31
Wege, A. K., Weber, F., Kroemer, A., Ortmann, O., Nimmerjahn, F., & Brockhoff, G. (2016) · Oncotarget · doi:10.18632/oncotarget.13159 · Cited by 30
Musolino, A., Naldi, N., Dieci, M. V., Zanoni, D., Rimanti, A., Boggiani, D., Sgargi, P., Generali, D., Piacentini, F., Ambroggi, M., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.51 · Cited by 29
Geva, R., Vecchione, L., Kalogeras, K. T., Jensen, B. V., Lenz, H., Yoshino, T., Páez, D., Montagut, C. O., Souglakos, J., Cappuzzo, F., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-307234 · Cited by 28
Huang, L., Chen, S., Yang, W., Xu, B., Huang, T., Yang, H., Zheng, H. Y., Wang, Y., Song, E., Zhang, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4337 · Cited by 23
Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
Mata, J. J., Rebollo-Liceaga, J., Martinez-Navarro, E., Manzano, R. G., Brugarolas, A., Juan, M., & Sureda, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.926289 · Cited by 23
Genetic Influences in Breast Cancer Drug Resistance
Daniyal, A., Santoso, I., Gunawan, N. H. P., Barliana, M. I., & Abdulah, R. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s284453 · Cited by 24
Musolino, A., Boggiani, D., Pellegrino, B., Zanoni, D., Sikokis, A., Missale, G., Silini, E. M., Maglietta, G., Frassoldati, A., & Michiara, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102927 · Cited by 20
Antitumor Immunity: Easy as 1, 2, 3 with Monoclonal Bispecific Trifunctional Antibodies?
Maher, J. F., & Adami, A. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1852 · Cited by 20
Margetuximab in HER2-positive metastatic breast cancer
Gradishar, W. J., O'Regan, R. M., Rimawi, M. F., Nordstrom, J. L., Rosales, M. K., & Rugo, H. S. (2023) · Future Oncology · doi:10.2217/fon-2022-1040 · Cited by 22
Natural killer cell phenotype is altered in HIV-exposed seronegative women
Zhao, N. Q., Vendrame, E., Ferreira, A.-M., Seiler, C., Ranganath, T., Alary, M., Labbé, A., Guédou, F. A., Poudrier, J., Holmes, S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238347 · Cited by 20
Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering
Xu, H., Guo, H.-F., Cheung, I. Y., & Cheung, N. V. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0221 · Cited by 19
Wang, D., Wei, X., Wang, Z.-Q., Lu, Y., Shi, S.-M., Wang, N., Qiu, M., Wang, F.-H., Wang, R.-J., Li, Y., et al. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s142620 · Cited by 19
Hirvinen, M., Heiskanen, R., Oksanen, M., Pesonen, S. K., Liikanen, I., Joensuu, T. K., Kanerva, A., Cerullo, V., & Hemminki, A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-193 · Cited by 19
Fiedler, W., Stoeger, H., Perotti, A., Gastl, G. A., Weidmann, J., Dietrich, B., Baumeister, H., Danielczyk, A., Goletz, S., Salzberg, M. O., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000381 · Cited by 17
Shimizu, C., Mogushi, K., Morioka, M. S., Yamamoto, H., Tamura, K., Fujiwara, Y., & Tanaka, H. (2015) · Breast Cancer · doi:10.1007/s12282-015-0614-y · Cited by 16
Miolo, G., Muraro, E., Martorelli, D., Lombardi, D., Scalone, S., Spazzapan, S., Massarut, S., Perin, T., Viel, E., Comaro, E., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-954 · Cited by 16
Clinical Perspectives on Targeting Therapies for Personalized Medicine
Singer, D. R. J., & Zaïr, Z. M. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.11.003 · Cited by 15
Deligne, C., Milcent, B., Josseaume, N., Teillaud, J., & Sibéril, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00950 · Cited by 15
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy
Rocca, A., Andreis, D., Fedeli, A., Maltoni, R., Sarti, S., Cecconetto, L., Pietri, E., Schirone, A., Bravaccini, S., Serra, P., et al. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1078311 · Cited by 16
Maskalenko, N. A., Zahroun, S., Tsygankova, O., Anikeeva, N., Sykulev, Y. K., & Campbell, K. S. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0384 · Cited by 13
Stein, M. M., Hrusch, C. L., Sperling, A. I., & Ober, C. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0038-8 · Cited by 13
De Novo Resistance Biomarkers to Anti-Her2 Therapies in Her2-Positive Breast Cancer
Madrid-Paredes, A., Cañadas‐Garre, M., Sánchez–Pozo, A., & Calleja‐Hernández, M. Á. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.88 · Cited by 12
Husna, S. M. N., & Wong, K. K. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.10.005 · Cited by 11
The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment
Wu, X., & Xiong, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111407 · Cited by 10
Cocca, M., Bedognetti, D., Bianca, M. L., Gasparini, P., & Girotto, G. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0778-z · Cited by 11
Exploiting Antibody Biology for the Treatment of Cancer
Khanna, V., Panyam, J., & Griffith, T. S. (2020) · Immunotherapy · doi:10.2217/imt-2019-0118 · Cited by 9
Kløve‐Mogensen, K., Steffensen, R., Masmas, T. N., Glenthøj, A. B., Jensen, C. F., Haunstrup, T. M., Ratcliffe, P., Höglund, P., Hasle, H., & Nielsen, K. R. (2023) · International Journal of Immunogenetics · doi:10.1111/iji.12614 · Cited by 8
Kløve‐Mogensen, K., Terp, S. K., & Steffensen, R. (2024) · Journal of Immunological Methods · doi:10.1016/j.jim.2024.113628 · Cited by 8
Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer
Gombos, A., Franzoi, M. A., & Awada, A. H. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1633306 · Cited by 8
Murphy, K. E., Niederer, H. A., King, K. S., Harris, E. C., Glass, S. M., & Cox, C. J. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000175 · Cited by 8
Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation
Bauer-Smith, H., Sudol, A. S. L., Beers, S. A., & Crispin, M. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130448 · Cited by 10
Pharmacogenetic Predictors of Response
Hertz, D. L., & Rae, J. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22909-6_8 · Cited by 6
Predictive Value of FcR Polymorphisms
Dolcetti, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4905 · Cited by 6
Furrer, D., Dragic, D., Chang, S.-L., Fournier, F., Droit, A., Jacob, S., & Diorio, C. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.63 · Cited by 6
Botticelli, A., Mazzuca, F., Borro, M., Mazzotti, E., Torre, M. L., Bonifacino, A., Ciabatta, F. R., Gentile, G., Maddalena, C., Simmaco, M., et al. (2015) · World Journal of Oncology · doi:10.14740/wjon934w · Cited by 4
Matlawska‐Wasowska, K., Gale, J. M., Nickl, C. K., Khalili, P., Shirley, B., Wilson, B. S., Vasef, M. A., & Winter, S. S. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0120-5 · Cited by 4
Breast Cancer Pharmacogenetics in the Era of Personalized Medicine
Yao, S., Maghsoudlou, D., & Ambrosone, C. B. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0088-2 · Cited by 4
FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients
Abdel-Wahed, M. A., Sabbour, G. S., Hamed, A. I., Kady, M. S. E., Mohammed, S. K., & Shaaban, M. A. A. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-76024-6 · Cited by 3
Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm
Soberino, J., Racca, F., Pérez-García, J. M., García‐Fernández, L., & Cortés, J. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00332-4 · Cited by 3
Rožman, S., Novaković, S., Grabnar, I., Cerkovnik, P., & Novaković, B. J. (2016) · Oncology Letters · doi:10.3892/ol.2016.4402 · Cited by 2
Monoclonal Antibodies for Cancer Therapy and Prevention
Zhang, H., Samanta, A., Nagai, Y., Tsuchiya, H., Ohtani, T., Cai, Z., Zhu, Z., Liu, J., & Greene, M. I. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00014-2 · Cited by 2
Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer
Fehm, T. N., Welslau, M., Müller, V., Lüftner, D., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Beierlein, M., et al. (2023) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2018-9053 · Cited by 2
Twomey, J. D., George, S., & Zhang, B. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf003 · Cited by 1
Way to go to exploit NK cells' versatile talents for cancer immunotherapy
Cho, D. (2014) · Blood Research · doi:10.5045/br.2014.49.3.139 · Cited by 1
Could Pharmacogenomics Improve Efficacy and Safety of Trastuzumab?
Yiannakopoulou, E. C. (2015) · Biochemistry & Pharmacology Open Access · doi:10.4172/2167-0501.1000e174 · Cited by 1
Chae, H., Yoo, C., Yoon, J.-A., Lee, H. J., Kim, K., Kim, J., Ahn, J., Jung, K. H., Gong, G., & Kim, S. (2018) · Journal of Breast Cancer · doi:10.4048/jbc.2018.21.1.45 · Cited by 1
Riller, Q., Varthaman, A., & Sibéril, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_9 · Cited by 1
The Potential Predictors in Chemotherapy Sensitivity
Kim, E., & Shin, H.-C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_19 · Cited by 1
Zheng, S., Wang, W., & Zhou, H. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse545 · Cited by 1
Metadata
- Authors
- Hurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y., Buyse, M., Mackey, J., Driga, A., Damaraju, S., Sliwkowski, M. X., Robert, N. J., Valero, V., Crown, J., Falkson, C., Brufsky, A., Pienkowski, T., Eiermann, W., Martin, M., Bee, V., Marathe, O., Slamon, D. J., & Timmerman, J. M.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Authors' Affiliations: 1University of California at Los Angeles, Los Angeles; 2Genentech, South San Francisco, California; 3International Drug Development Institute, Louvain-la-Neuve, Belgium; 4Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; 5Virginia Cancer Specialists, US Oncology, Fairfax, Virginia; 6University of Texas MD Anderson Cancer Center, Houston, Texas; 7St. Vincent's Hospital, Dublin, Ireland; 8University of Alabama at Birmingham, Birmingham, Alabama; 9University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 10Cancer Center, Warsaw, Poland; 11Redcross Women's Hospital, Muenchen, Germany; 12Hospital Gregorio Maranon, Madrid, Spain; and 13Breast Cancer International Research Group (BCIRG), Paris, France
- Corresponding author
- Hurvitz, Sara A.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-06-14
- Volume
- 18
- Issue
- 12
- Pages
- 3478-3486
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3821872
- OpenAlex
- W2162904392
- Cited by
- 115
- References
- 27
- Citations by year
- 2025: 3 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 10 · 2018: 6 · 2017: 11 · 2016: 14 · 2015: 16 · 2014: 13 · 2013: 9 · 2012: 5
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1ul1rr033176-01, UL1TR000124)
- National Cancer Institute (P30CA016042)
- National Center for Research Resources (UL1-RR-033176)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- FcγRIIIa, FCGR2A, single nucleotide polymorphisms, trastuzumab, HER2-positive breast cancer, disease-free survival, antibody-dependent cellular cytotoxicity, pharmacogenetics, adjuvant chemotherapy
- MeSH terms
- Trastuzumab, Adult, Aged, Breast Neoplasms, Female, Gene Frequency, Genotype, Humans, Middle Aged, Treatment Outcome, Receptors, IgG, Amino Acid Substitution, Polymorphism, Single Nucleotide, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
